Congratulations to the guys and gals on this board that stood strong in defense of the company. Setting legal decisions aside, I believe there are more important basic assumptions to be drawn from this activity.
Despite our reservations regarding NP we believe that he is doing his utmost best to bring LL to market. His perseverance is contagious and it has been transferred to shareholders. His shortcomings are well-know and well documented, but he is trustworthy.
The reconstructed team would not be part of Cytodyn if they did not also believe in LL. Their confidence spilled over to shareholders.
Despite lack of confidence exhibited by the FDA; competition by big pharma, and organized short attacks, shareholders believe the "anecdotes". LL works. It works against HIV; it works against triple negative breast cancer; it mitigates moderate to severe COVID; it works to mitigate long-haulers syndrome; and it saves lives.
Shareholders have settled in for the long haul, no pun intended. There will be no magic bullet to move the share price to $100 over night. Success will depend on the thousands of sick people who participate in the trials, precise trial parameters, undeniable positive results from numerous platforms, and results that are indisputable concerning safety and efficacy.
There is no way this number of shareholders would have stood firm if there was not basic, deep-rooted faith that LL works. Nothing else is as important for those past, current, and future patients who have or will benefit from LL. That's why shareholders participate on this board and have rejected the interlopers.
Only time will tell if we are right or wrong, but the team we have chosen to get to the big dance is not in question.
Despite our reservations regarding NP we believe that he is doing his utmost best to bring LL to market. His perseverance is contagious and it has been transferred to shareholders. His shortcomings are well-know and well documented, but he is trustworthy.
The reconstructed team would not be part of Cytodyn if they did not also believe in LL. Their confidence spilled over to shareholders.
Despite lack of confidence exhibited by the FDA; competition by big pharma, and organized short attacks, shareholders believe the "anecdotes". LL works. It works against HIV; it works against triple negative breast cancer; it mitigates moderate to severe COVID; it works to mitigate long-haulers syndrome; and it saves lives.
Shareholders have settled in for the long haul, no pun intended. There will be no magic bullet to move the share price to $100 over night. Success will depend on the thousands of sick people who participate in the trials, precise trial parameters, undeniable positive results from numerous platforms, and results that are indisputable concerning safety and efficacy.
There is no way this number of shareholders would have stood firm if there was not basic, deep-rooted faith that LL works. Nothing else is as important for those past, current, and future patients who have or will benefit from LL. That's why shareholders participate on this board and have rejected the interlopers.
Only time will tell if we are right or wrong, but the team we have chosen to get to the big dance is not in question.
18
